EDTA Chelation vs PNC-27
A side-by-side research comparison of EDTA Chelation and PNC-27 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | EDTA Chelation | PNC-27 |
|---|---|---|
| Full name | Calcium Disodium EDTA (CaNa2EDTA) | PNC-27 (p53-Derived Anticancer Peptide) |
| Category | Detox & Antioxidant | Detox & Antioxidant |
| Status | FDA Approved (lead poisoning) / Off-label | Research compound (preclinical) |
| Mechanism | Hexadentate chelator forming stable complexes with Pb²⁺, Cd²⁺, Hg²⁺, and Ca²⁺ from arterial plaque. Metal-EDTA complexes are water-soluble and excreted renally. Also reduces oxidative stress from heavy metal catalyzed Fenton reactions. | Contains a p53 domain fused to a membrane-penetrating sequence. It is proposed to bind HDM-2 that is preferentially expressed on cancer cell membranes, forming pores that cause selective necrosis of cancer cells while reportedly sparing normal cells in studies. |
| Molecular weight | 374.27 Da (disodium EDTA) | ~3.2 kDa |
| Half-life | ~1.5 hours (IV) | Short (peptide) |
| Bioavailability | ~5% oral; 100% IV | Injection (research) |
| Typical dose | 1.5-3g IV over 1-3 hours | Not established for humans |
| Frequency | Weekly or biweekly | Research only |
| Route | Intravenous infusion | Injection (research) |
EDTA Chelation reported benefits
- Lead and heavy metal removal
- Reduced cardiovascular events (TACT trial)
- Arterial calcium removal
- Reduced oxidative stress
- Improved vascular function
PNC-27 reported benefits
- Selective cancer-cell targeting (preclinical)
- p53/HDM-2 mechanism of interest
- Reported sparing of normal cells (studies)
Related comparisons
Research and educational reference only. Not medical advice.